- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02499380
Changes in Lung Physiology and Cardiac Performance in Patients With Emphysema Post Bilateral RePneu Coil Treatment
July 15, 2021 updated by: Boston Scientific Corporation
The objective of this post-marketing study is to advance the understanding of the mechanism of action of the CE marked RePneu Coil by observing changes in lung physiology and cardiac performance in patients with emphysema treated with the RePneu Coils, when used as intended.
Study Overview
Study Type
Observational
Enrollment (Actual)
20
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Grosshansdorf, Germany
- LungenClinic
-
Heidelberg, Germany
- Thoraxklinik
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Adult subjects diagnosed with emphysematous type of COPD
Description
Inclusion Criteria:
- Adult subjects diagnosed with emphysematous type of COPD.
- CT scan indicates bilateral emphysema, with sufficient lung parenchyma for coil deployment (based on PneumRx CT scoring) criteria.
- Subject has post-bronchodilator FEV1 ≤45% predicted.
- Subject has Total Lung Capacity >100% predicted.
- Subject has residual volume (RV) ≥175% predicted.
- Subject has marked dyspnea scoring ≥2 on mMRC scale of 0-4.
- Subject read, understood and signed the Informed Consent form.
- Subject has received Pneumococcal and Influenza vaccinations consistent with local recommendations and/or policy.
Exclusion Criteria:
- Subject has co-morbidities that may significantly reduce subject's ability to improve exercise capacity (e.g. severe arthritis, planned knee surgery) or baseline limitation not due to dyspnea.
- Subject has a change in FEV1 >20% (or, for subjects with pre-bronchodilator FEV1 below 1 L, a change of > 200 mL) post-bronchodilator unless investigator can confirm by other means that subject does not have asthma.
Subject has severe gas exchange abnormalities as defined by:
- PaCO2 >55 mm Hg
- PaO2 <45 mm Hg on room air (High altitude criterion: PaO2 <30 mm Hg)
- Subject has severe pulmonary hypertension defined by right ventricular systolic pressure >50 mm Hg via right heart catheterization and/or echocardiogram.
- Subject has evidence of other severe disease (such as, but not limited to, lung cancer or renal failure), which in the judgment of the investigator may compromise survival of the subject for the duration of the study.
- Subject is pregnant or lactating, or plans to become pregnant within the study timeframe.
- Subject has an inability to tolerate bronchoscopy under moderate sedation or general anesthesia.
- Subject has clinically significant bronchiectasis.
- Subject has had previous LVR surgery, lung transplantation, lobectomy or other BLVR treatment in either lung.
- Subject has participated in studies to treat COPD using high dose radiation.
- Subject has been involved in pulmonary drug or device studies within 30 days prior to this study.
- Subject is chronically taking >20 mg prednisone (or equivalent dose of a similar steroid) daily.
- Subject requires high level chronic immunomodulatory therapy to treat a moderate to severe chronic inflammatory autoimmune disorder.
- Subject is on any type of antiplatelet or anticoagulant therapy which cannot be stopped for seven (7) days prior to procedure.
- Subject has a sensitivity or allergy to Nickel.
- Subject has a known sensitivity to drugs required to perform bronchoscopy.
- Subject has been diagnosed with alpha-1 antitrypsin deficiency (AATD).
- Subject has any other disease, condition(s) or habit(s) that would interfere with completion of study and follow-up assessments, would increase risks of bronchoscopy or assessments, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Treatment
Patients treated with PneumRx Coil System
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in 6 Minute Walk Distance (6MWD)
Time Frame: Baseline, 12 months post initial treatment
|
Changes in distance traveled during a 6 minute walk test (6MWT).
Initial baseline measurement was taken prior to the treatment with the RePneu coil and the second measurement was taken 12 months after the initial treatment of the RePneu coil.
6MWD was measured in meters.
|
Baseline, 12 months post initial treatment
|
Changes in 6 Minute Walk Distance (6MWD)
Time Frame: Baseline, 3 months post final treatment
|
Changes in distance traveled during a 6 minute walk test (6MWT).
Initial baseline measurement was taken prior to the treatment with the RePneu coil and the second measurement was taken 3 months after final treatment of the RePneu coil.
6MWD was measured in meters.
|
Baseline, 3 months post final treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 9, 2015
Primary Completion (Actual)
December 8, 2017
Study Completion (Actual)
October 20, 2018
Study Registration Dates
First Submitted
May 27, 2015
First Submitted That Met QC Criteria
July 13, 2015
First Posted (Estimate)
July 16, 2015
Study Record Updates
Last Update Posted (Actual)
July 19, 2021
Last Update Submitted That Met QC Criteria
July 15, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLN0017
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Emphysema
-
Pulmonx CorporationRecruitingEmphysema or COPD | Emphysema, PulmonarySpain, Germany, Italy, Australia
-
Pulmonx CorporationActive, not recruiting
-
Heidelberg UniversityUnknown
-
Royal Brompton & Harefield NHS Foundation TrustCompletedHeterogeneous EmphysemaUnited Kingdom
-
Aeris TherapeuticsCompleted
-
Pulmonx CorporationCompleted
-
University Medical Center GroningenCompletedEmphysema or COPDNetherlands
-
Aeris TherapeuticsCompleted
-
University Medical Center GroningenRecruitingEmphysema or COPDNetherlands
-
Rabin Medical CenterUnknownPatients With Advanced Homogeneous EmphysemaIsrael
Clinical Trials on PneumRx Coil System
-
Boston Scientific CorporationPneumRx, Inc.TerminatedEmphysemaUnited Kingdom, Spain, Germany, Switzerland, Austria, Denmark
-
University Hospital, SaarlandWithdrawnEmphysema | Chronic Obstructive Lung Disease | Alpha-1-Antitrypsin DeficiencyDenmark, Germany
-
Boston Scientific CorporationPneumRx, Inc.Completed
-
Boston Scientific CorporationPneumRx, Inc.Completed
-
Zhuhai Tonbridge Medical Tech. Co., Ltd.CompletedIntracranial AneurysmsChina
-
St. Joseph's Healthcare HamiltonPeter Boris Centre for Addictions Research (PBCAR)Recruiting
-
Vascular Neurology of Southern California Inc.RecruitingAneurysm | Subarachnoid Hemorrhage, Aneurysmal | Intracranial Aneurysm | Ruptured Aneurysm | Cerebral Aneurysm UnrupturedUnited States
-
Centre for Addiction and Mental HealthCanadian Institutes of Health Research (CIHR); BrainswayCompleted
-
Texas Cardiac Arrhythmia Research FoundationRecruitingLeft Atrial Appendage Incomplete ClosureUnited States
-
BrainswayCompletedMajor Depressive DisorderUnited States, Canada, Germany, Israel, France